Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

Exclusion Criteria

• •1. Active infection with herpes simplex virus (HSV);
• •2. Pregnant or breast feeding subjects;
• •3. Any concurrent condition requiring the continued use of systemic or topical steroids (excluding inhaled and eye drop-containing corticosteroids) or the use of immunosuppressive agents. All other corticosteroids must be discontinued \> 4 weeks prior to Day 1 of treatment;
• •4. Administration of any blood product within 3 months of enrollment;
• •5. Administration of any vaccine within 6 weeks of enrollment;
• •6. Patient is currently participating or has participated in a study with an investigational compound or device other than VGX-3100 within 30 days of signing informed consent;
• •7. Metal implants at the site of injection;
• •8. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements;
• •9. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (i.e. infections disease) illness must not be enrolled into this study;
• •10. Any other conditions judged by the investigator that would limit the evaluation of a subject.